Sustained unresponsiveness to peanut after long-term peanut epicutaneous immunotherapy

Terri F. Brown-Whitehorn; Frédéric de Blay; Jonathan M. Spergel; Todd D. Green; Aurélie Peillon; Hugh A. Sampson; Dianne E. Campbell

doi:10.1016/j.jaip.2020.08.017

Sustained unresponsiveness to peanut after long-term peanut epicutaneous immunotherapy

Terri F. Brown-Whitehorn, Frédéric de Blay, Jonathan M. Spergel, Todd D. Green, Aurélie Peillon, Hugh A. Sampson, Dianne E. Campbell

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Original language	English
Pages (from-to)	524-526
Number of pages	3
Journal	Journal of Allergy and Clinical Immunology: In Practice
Volume	9
Issue number	1
DOIs	https://doi.org/10.1016/j.jaip.2020.08.017
State	Published - Jan 2021

Access to Document

10.1016/j.jaip.2020.08.017

Cite this

@article{d97ab44259714567ba45d5cc50be303a,

title = "Sustained unresponsiveness to peanut after long-term peanut epicutaneous immunotherapy",

author = "Brown-Whitehorn, {Terri F.} and {de Blay}, Fr{\'e}d{\'e}ric and Spergel, {Jonathan M.} and Green, {Todd D.} and Aur{\'e}lie Peillon and Sampson, {Hugh A.} and Campbell, {Dianne E.}",

note = "Funding Information: Conflicts of interest: T. D. Green, A. Peillon, H. A. Sampson, and D. E. Campbell are employees of DBV Technologies. T. Brown-Whitehorn is a DBV Technologies grant recipient, clinical advisory board member, and consultant. F. de Blay reported receiving grants and/or personal fees from Stallergenes Greer, Chiesi, ALK, Mundipharma, and Novartis, as well as serving as a board member for Stallergenes Greer, Novartis, ALK, Mundipharma, Meda Pharma, Boehringer Ingelheim, and AstraZeneca. J. M. Spergel reports board membership from the American Partnership for Eosinophilic Disorders and the International Food Protein-Induced Enterocolitis Syndrome Association; consultancy fees from DBV Technologies, Sanofi/Regeneron, and Medscape; speaker fees from Abbott; and grants to his institution from the National Institutes of Health and End Allergies Together and Aimmune. Funding Information: Conflicts of interest: T. D. Green, A. Peillon, H. A. Sampson, and D. E. Campbell are employees of DBV Technologies. T. Brown-Whitehorn is a DBV Technologies grant recipient, clinical advisory board member, and consultant. F. de Blay reported receiving grants and/or personal fees from Stallergenes Greer , Chiesi , ALK , Mundipharma , and Novartis , as well as serving as a board member for Stallergenes Greer, Novartis, ALK, Mundipharma, Meda Pharma, Boehringer Ingelheim, and AstraZeneca. J. M. Spergel reports board membership from the American Partnership for Eosinophilic Disorders and the International Food Protein-Induced Enterocolitis Syndrome Association; consultancy fees from DBV Technologies, Sanofi/Regeneron, and Medscape; speaker fees from Abbott; and grants to his institution from the National Institutes of Health and End Allergies Together and Aimmune . ",

year = "2021",

month = jan,

doi = "10.1016/j.jaip.2020.08.017",

language = "English",

volume = "9",

pages = "524--526",

journal = "Journal of Allergy and Clinical Immunology: In Practice",

issn = "2213-2198",

publisher = "Elsevier",

number = "1",

}

TY - JOUR

T1 - Sustained unresponsiveness to peanut after long-term peanut epicutaneous immunotherapy

AU - Brown-Whitehorn, Terri F.

AU - de Blay, Frédéric

AU - Spergel, Jonathan M.

AU - Green, Todd D.

AU - Peillon, Aurélie

AU - Sampson, Hugh A.

AU - Campbell, Dianne E.

N1 - Funding Information: Conflicts of interest: T. D. Green, A. Peillon, H. A. Sampson, and D. E. Campbell are employees of DBV Technologies. T. Brown-Whitehorn is a DBV Technologies grant recipient, clinical advisory board member, and consultant. F. de Blay reported receiving grants and/or personal fees from Stallergenes Greer, Chiesi, ALK, Mundipharma, and Novartis, as well as serving as a board member for Stallergenes Greer, Novartis, ALK, Mundipharma, Meda Pharma, Boehringer Ingelheim, and AstraZeneca. J. M. Spergel reports board membership from the American Partnership for Eosinophilic Disorders and the International Food Protein-Induced Enterocolitis Syndrome Association; consultancy fees from DBV Technologies, Sanofi/Regeneron, and Medscape; speaker fees from Abbott; and grants to his institution from the National Institutes of Health and End Allergies Together and Aimmune. Funding Information: Conflicts of interest: T. D. Green, A. Peillon, H. A. Sampson, and D. E. Campbell are employees of DBV Technologies. T. Brown-Whitehorn is a DBV Technologies grant recipient, clinical advisory board member, and consultant. F. de Blay reported receiving grants and/or personal fees from Stallergenes Greer , Chiesi , ALK , Mundipharma , and Novartis , as well as serving as a board member for Stallergenes Greer, Novartis, ALK, Mundipharma, Meda Pharma, Boehringer Ingelheim, and AstraZeneca. J. M. Spergel reports board membership from the American Partnership for Eosinophilic Disorders and the International Food Protein-Induced Enterocolitis Syndrome Association; consultancy fees from DBV Technologies, Sanofi/Regeneron, and Medscape; speaker fees from Abbott; and grants to his institution from the National Institutes of Health and End Allergies Together and Aimmune .

PY - 2021/1

Y1 - 2021/1

UR - http://www.scopus.com/inward/record.url?scp=85092012484&partnerID=8YFLogxK

U2 - 10.1016/j.jaip.2020.08.017

DO - 10.1016/j.jaip.2020.08.017

M3 - Article

C2 - 32835872

AN - SCOPUS:85092012484

SN - 2213-2198

VL - 9

SP - 524

EP - 526

JO - Journal of Allergy and Clinical Immunology: In Practice

JF - Journal of Allergy and Clinical Immunology: In Practice

IS - 1

ER -